# Sandar Aye

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sandar-aye/

## Facts

| Field | Value |
| --- | --- |
| Citations | 76 |
| Field | Dementia and Cognitive Impairment Research |
| h-index | 4 |
| i10-index | 3 |
| Last Known Institution | Karolinska Institutet |
| OpenAlex ID | https://openalex.org/A5039818272 |
| ORCID iD | 0000-0003-1360-4834 |
| Works | 20 |

## Researcher papers

- [Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis](https://scholariq.org/papers/health-related-quality-of-life-in-subjective-cognitive-decline-and-mild/)
- [Optimising Alzheimer's Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment](https://scholariq.org/papers/optimising-alzheimer-s-disease-diagnosis-and-treatment-assessing-cost-utility-of-2/)
- [Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease](https://scholariq.org/papers/point-of-view-challenges-in-implementation-of-new-immunotherapies-for-alzheimer/)
- [Effect of mortality in cost‐effectiveness modeling of disease‐modifying treatment for Alzheimer's disease](https://scholariq.org/papers/effect-of-mortality-in-cost-effectiveness-modeling-of-disease-modifying/)
- [IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer’s Disease](https://scholariq.org/papers/ipecad-modeling-workshop-2023-cross-comparison-challenge-on-cost-effectiveness/)
- [Costs of Care in Relation to Alzheimer’s Disease Severity in Sweden: A National Registry-Based Cohort Study](https://scholariq.org/papers/costs-of-care-in-relation-to-alzheimer-s-disease-severity-in-sweden-a-national/)
- [Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer’s disease](https://scholariq.org/papers/clinical-translation-of-fluid-imaging-and-digital-biomarkers-for-alzheimer-s/)
- [Optimising Alzheimer's Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment](https://scholariq.org/papers/optimising-alzheimer-s-disease-diagnosis-and-treatment-assessing-cost-utility-of/)
- [The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer’s Disease in Sweden](https://scholariq.org/papers/the-cost-effective-price-of-lecanemab-for-patients-with-early-alzheimer-s/)
- [MSR136 IPECAD Modeling Workshop 2023 Cross Comparison Challenge on Cost-Effectiveness Models in Alzheimer's Disease and Related Dementias](https://scholariq.org/papers/msr136-ipecad-modeling-workshop-2023-cross-comparison-challenge-on-cost/)
- [Deciphering Perspectives: A European Survey on Clinical Decision Support Tools for Dementia and Alzheimer’s Disease](https://scholariq.org/papers/deciphering-perspectives-a-european-survey-on-clinical-decision-support-tools/)

## Researcher topics

- [Dementia and Cognitive Impairment Research](https://scholariq.org/topics/dementia-and-cognitive-impairment-research/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Alzheimer's disease research and treatments](https://scholariq.org/topics/alzheimer-s-disease-research-and-treatments/)
- [Frailty in Older Adults](https://scholariq.org/topics/frailty-in-older-adults/)
- [Cholinesterase and Neurodegenerative Diseases](https://scholariq.org/topics/cholinesterase-and-neurodegenerative-diseases/)

## Researcher university

- [Karolinska Institutet](https://scholariq.org/institutions/karolinska-institutet/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.